NovoCure Ltd serves in the healthcare sector of United States. Its business involves commercial stage oncology operations involving therapies to cure critical tumors. Its key offering is the TTFields therapy, which is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, thereby leading to cancer cell death. NovoCure derives its major revenues in the United States, through the sale of TTFields delivery system, which includes a portable electric field generator, transducer arrays, rechargeable batteries, and accessories.